Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir prophylaxis in CMV-seronegative allo-HSCT recipients with CMV-seropositive donors
2024-516011-24-01Phase 2Authorised
- Sponsor
- Grupo Español de Trasplante Hematopoyético
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letermovir in cytomegalovirus disease (CMV), sponsored by Grupo Español de Trasplante Hematopoyético. Primary endpoint: Primary endpoint: incidence of clinically significant CMV infection. Planned start Oct 2024; status: authorised.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2024-516011-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516011-24-01.